Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 9Thoracic 5Genitourinary 4Breast 4Dermatologic 2Sarcoma 1Head & Neck 1

Conditions

Breast Neoplasms 28Pancreatic Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Breast Neoplasms, Male 4Sarcoma 3Rectal Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colonic Neoplasms 3Kidney Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Cancer Metastatic 2Brain Neoplasms 2Bile Duct Neoplasms 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Irinotecan × Breast × Clear all
NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

SN BioScience

Phase 1 Completed
21 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT06769425 2025-06-24

HS-10502

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
157 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡